281 related articles for article (PubMed ID: 23546450)
1. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.
Chen Y; Sun Y; Chen L; Xu X; Zhang X; Wang B; Min L; Liu W
Mol Med Rep; 2013 May; 7(5):1579-84. PubMed ID: 23546450
[TBL] [Abstract][Full Text] [Related]
2. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
4. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
5. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling.
Yin Y; Wang X; Li T; Ren Q; Li L; Sun X; Zhang B; Wang X; Han H; He Y; Cao Z; Sun X; Zhou Z
Cancer Med; 2020 Feb; 9(4):1544-1552. PubMed ID: 31899608
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells.
Chen Y; Zuo J; Liu Y; Gao H; Liu W
Chin J Cancer; 2010 Dec; 29(12):1006-11. PubMed ID: 21114921
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
[TBL] [Abstract][Full Text] [Related]
11. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
12. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
13. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
14. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis.
Wang X; Chen X; Wang R; Xiao P; Xu Z; Chen L; Hang W; Ruan A; Yang H; Zhang X
Oncol Rep; 2013 Aug; 30(2):643-50. PubMed ID: 23754305
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
Tryndyak VP; Beland FA; Pogribny IP
Int J Cancer; 2010 Jun; 126(11):2575-83. PubMed ID: 19839049
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
[TBL] [Abstract][Full Text] [Related]
17. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
18. Targets of miR-200c mediate suppression of cell motility and anoikis resistance.
Howe EN; Cochrane DR; Richer JK
Breast Cancer Res; 2011 Apr; 13(2):R45. PubMed ID: 21501518
[TBL] [Abstract][Full Text] [Related]
19. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells.
Kim MR; Choi HK; Cho KB; Kim HS; Kang KW
Cancer Sci; 2009 Oct; 100(10):1834-41. PubMed ID: 19681904
[TBL] [Abstract][Full Text] [Related]
20. Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma.
Cong N; Du P; Zhang A; Shen F; Su J; Pu P; Wang T; Zjang J; Kang C; Zhang Q
Oncol Rep; 2013 Apr; 29(4):1579-87. PubMed ID: 23381389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]